Neurology Central

Could combination therapy be the future of neuroblastoma treatment?

Scientists from the Children’s Cancer Institute Australia for Medical Research (Sydney, Australia) have developed a novel therapy for treating neuroblastoma that is effective in mice and has the potential to be utilized in humans.

Research on this new treatment method, involving a combination of CBL0137 and panobinostat, was presented at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 2018 (13–16 November, Dublin, Ireland).

Neuroblastoma, often found in the adrenal glands, is currently the leading cause of cancer deaths in children under the age of five. Children with aggressive forms of this cancer often have a survival rate of below 50%, despite receiving intensive treatment.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.